Review
Engineering, Multidisciplinary
Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen
Summary: The modification of therapeutic antibodies is booming in research and development to improve efficacy. China, as an active player in the biopharmaceutical field, shows a great demand and potential in this area.
Article
Oncology
Guang Wu, Lan Li, Mengnan Liu, Chunyan Chen, Guangze Wang, Zewei Jiang, Yaqian Qin, Licai He, Hongzhi Li, Jiawei Cao, Haihua Gu
Summary: The generated HzMUC1-ADC demonstrated promising targeted therapy potential for pancreatic cancer, as it inhibited tumor cell growth, induced apoptosis, and significantly reduced xenograft tumor growth in vivo.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu
Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.
Review
Biochemistry & Molecular Biology
Xiu-Fang Li, Chen-Fu Liu, Guo-Wu Rao
Summary: The human epidermal growth factor receptor family, including HER1/EGFR/ErbB1, HER2/NEU/ErbB2, HER3/ErbB3 and HER4/ErbB4, belongs to transmembrane receptor tyrosine kinases (RTKs) and participates in signal transduction and oncogenesis. These receptors have similar structures, with extracellular and intracellular domains serving different functions.
CURRENT MEDICINAL CHEMISTRY
(2021)
Review
Oncology
Sneha Vivekanandhan, Keith L. Knutson
Summary: Trastuzumab, a humanized monoclonal antibody targeting HER2 protein, is a widely used biologic for breast cancer treatment with multiple mechanisms of action including cell cycle arrest, apoptosis induction, and ADCC. However, resistance mechanisms such as immune suppression, vascular mimicry, breast cancer stem cell generation, long non-coding RNA deregulation, and metabolic escape have been identified in some patients, indicating the need for personalized combination therapies to improve patient survival.
Review
Biochemistry & Molecular Biology
Victor Albarran, Diana Isabel Rosero, Jesus Chamorro, Javier Pozas, Maria San Roman, Ana Maria Barrill, Victor Alia, Pilar Sotoca, Patricia Guerrero, Juan Carlos Calvo, Inmaculada Orejana, Patricia Perez de Aguado, Pablo Gajate
Summary: Metastatic urothelial cancer is a major cause of cancer-related death, but new treatment approaches targeting Her-2 show promise, especially with the emergence of antibody-drug conjugates as a novel therapy for advanced cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Nicole L. Wittwer, Michael P. Brown, Vasilios Liapis, Alexander H. Staudacher
Summary: Pancreatic cancer is a major cause of cancer-related death, and the current treatment options have limited impact on survival. Late detection and metastasis often make curative surgery impossible. Antibody drug conjugates (ADCs) have the potential to improve targeted treatment and reduce toxicity. This paper reviews the literature on ADC targets for pancreatic cancer, summarizes ongoing clinical trials, and discusses strategies to improve their therapeutic window.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Jindong Xie, Yutian Zou, Ting Gao, Liming Xie, Duxun Tan, Xiaoming Xie
Summary: This article provides an overview of the therapeutic landscape of HER2+BC by reviewing research results and introducing the latest evidence, aiming to provide a reference for clinical treatment.
Article
Oncology
Rachel Hudson, Hang-Ping Yao, Sreedhar Reddy Suthe, Dhavalkumar Patel, Ming-Hai Wang
Summary: This study evaluates the use of a novel antibody-drug conjugate, PCMC1D3-DCM, in targeting MET for cancer therapy. Results demonstrate the effectiveness of PCMC1D3-DCM in inhibiting tumor growth in vitro and in vivo.
CURRENT CANCER DRUG TARGETS
(2022)
Review
Cell Biology
Mark Barok, Maija Puhka, Narjes Yazdi, Heikki Joensuu
Summary: Antibody-drug conjugates (ADCs) are a new class of anti-cancer drugs that can selectively deliver cytotoxic drugs to cancer cells, leading to reduced systemic exposure and a wider therapeutic window. Research suggests that extracellular vesicles (EVs) may mediate both the anti-cancer effects and adverse effects of ADCs.
JOURNAL OF EXTRACELLULAR VESICLES
(2021)
Review
Immunology
Jia Mai, Limei Wu, Ling Yang, Ting Sun, Xiaojuan Liu, Rutie Yin, Yongmei Jiang, Jinke Li, Qintong Li
Summary: Epithelial ovarian cancer is a deadly gynecological cancer, and targeting the folate receptor alpha has shown promise in its treatment. Various modalities, including antibody-drug conjugates, monoclonal antibodies, and small molecules, have been explored to exploit this target for effective therapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Santosh Renuse, Vijay S. Madamsetty, Dong-Gi Mun, Anil K. Madugundu, Smrita Singh, Savita Udainiya, Kiran K. Mangalaparthi, Min-Sik Kim, Ren Liu, S. Ram Kumar, Valery Krasnoperov, Mark Truty, Rondell P. Graham, Parkash S. Gill, Debabrata Mukhopadhyay, Akhilesh Pandey
Summary: Pancreatic cancer, especially pancreatic ductal adenocarcinoma, is a deadly malignancy with poor response to traditional chemotherapies. Protein tyrosine kinases are commonly hyperactivated in cancers, making them potential therapeutic targets. The use of patient-derived tumor xenografts (PDXs) in animal models, such as mice, can help identify hyperactivated kinases for targeted therapies.
Article
Medicine, Research & Experimental
Tashbib Khan, Nicholas J. Lyons, Madeline Gough, Kayden K. X. Kwah, Tahleesa J. Cuda, Cameron E. Snell, Brian W. Tse, Kamil A. Sokolowski, Lesley A. Pearce, Timothy E. Adams, Stephen E. Rose, Simon Puttick, Marina Pajic, Mark N. Adams, Yaowu He, John D. Hooper, Thomas Kryza
Summary: This study evaluated the rationale of targeting CDCP1 with ADCs and demonstrated the efficacy of CDCP1-directed ADCs against multiple malignant tumors. CDCP1 expression was found to be elevated in the majority of cancers and restricted in normal tissues. CDCP1-directed ADCs exhibited robust anti-tumor effects both in vitro and in pre-clinical cancer models.
Review
Oncology
Elizabeth Sakach, Ruth Sacks, Kevin Kalinsky
Summary: Trop-2 is a new target for the treatment of breast cancer, with potential therapeutic benefits for metastatic and resistant patients. Inhibitors of Trop-2 have emerged as important treatment options, and ongoing studies investigate combination therapies and its use in early stage disease.
Article
Biochemistry & Molecular Biology
Yuka Tanaka, Maho Murata, Che-Hung Shen, Masutaka Furue, Takamichi Ito
Summary: The study found that high expression of NECTIN4 is associated with disease-free survival in melanoma, and in BRAFi-resistant melanoma cells, both NECTIN4 and the PI3K/Akt pathway are upregulated. Inhibiting NECTIN4 can increase the sensitivity of BRAFi-resistant cells to BRAFi, offering a novel treatment strategy for melanoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Medicinal
Surendra R. Punganuru, A. G. M. Mostofa, Hanumantha Rao Madala, Debasish Basak, Kalkunte S. Srivenugopal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2016)
Review
Pharmacology & Pharmacy
A. G. M. Mostofa, Md Kamal Hossain, Debasish Basak, Muhammad Shahdaat Bin Sayeed
FRONTIERS IN PHARMACOLOGY
(2017)
Review
Biotechnology & Applied Microbiology
Fabliha Ahmed Chowdhury, Md Kamal Hossain, A. G. M. Mostofa, Maruf Mohammad Akbor, Muhammad Shahdaat Bin Sayeed
BIOMED RESEARCH INTERNATIONAL
(2018)
Article
Oncology
A. G. M. Mostofa, Surendra R. Punganuru, Hanumantha Rao Madala, Kalkunte S. Srivenugopal
Article
Medical Laboratory Technology
Mohammad Safiqul Islam, Maizbha Uddin Ahmed, Muhammad Shandaat Bin Sayeed, Abdullah Al Maruf, A. G. M. Mostofa, Syed Md Akram Hussain, Yearul Kabir, Ann K. Daly, Abul Hasnat
CLINICA CHIMICA ACTA
(2013)
Article
Integrative & Complementary Medicine
Muhammad Shahdaat Bin Sayeed, A. G. M. Mostofa, F. M. Touhidul Islam Ferdous, Md Siddiqul Islam
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
(2013)
Article
Plant Sciences
Muhammad Shandaat Bin Sayeed, Tahiatul Shams, Sarder Fahim Hossain, Md. Rezowanur Rahman, A. G. M. Mostofa, Mohammad Fahim Kadir, Sharif Mahmood, Md. Asaduzzaman
JOURNAL OF ETHNOPHARMACOLOGY
(2014)
Article
Oncology
Mohammad Safiqul Islam, A. G. M. Mostofa, Maizbha Uddin Ahmed, Muhammad Shahdaat Bin Sayeed, Md. Rajib Hassan, Abul Hasnat
Review
Biochemistry & Molecular Biology
A. G. M. Mostofa, Surendra R. Punganuru, Hanumantha Rao Madala, Mohammad Al-Obaide, Kalkunte S. Srivenugopal
Article
Medicine, Research & Experimental
Ameya Paranjpe, Nathan I. Bailey, Santhi Konduri, George C. Bobustuc, Francis Ali-Osman, Mohd. A. Yusuf, Surendra R. Punganuru, Hanumantha Rao Madala, Debasish Basak, A. G. M. Mostofa, Kalkunte S. Srivenugopal
JOURNAL OF BIOMEDICAL RESEARCH
(2016)